Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

C-800-01

PharmaDeviceNews C-800-01

Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.

Pharma & Biotech

Agenus BOT+BAL shows long-term survival in refractory MSS colorectal cancer

by Pallavi Madhiraju
November 7, 2026
0 Comments

Agenus reports durable BOT+BAL survival in refractory MSS colorectal cancer, but a post-hoc Phase 1b analysis still needs randomised confirmation.

Read More

Latest news and features

Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit?
Rybrevant Faspro shrank tumours in 42% of heavily treated head and neck cancer patients. Can Phase 3 confirm the benefit?
Can Samsung Bioepis challenge Keytruda after its U.S. patent cliff begins in 2028?
Siemens Healthineers carves out diagnostics business as Olyrian after Q4 margin falls to 5.4%
Johnson & Johnson tests Rybrevant beyond NSCLC as OrigAMI-5 Phase 3 trial advances
Immunocore saw 70% of first-line patients alive at two years. Can two T-cell engagers really beat KIMMTRAK alone?
Agenus BOT+BAL shows long-term survival in refractory MSS colorectal cancer
Bristol Myers Squibb Camzyos franchise reaches $1.15bn as pediatric evidence expands
MetaVia’s tiny Phase 1 obesity study just posted 13.5% weight loss and a 68% liver-fat reduction. How much can investors trust yet?
Onkos can put its antibacterial coating on more implants. The FDA claim stops well short of preventing infection
Can Moderna sustain its comeback beyond COVID vaccines and intismeran?
Immunocore reports 70% two-year survival with dual T-cell engager combination in uveal melanoma

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.